FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948441106> ?p ?o ?g. }

• W2948441106 endingPage "12" @default.
• W2948441106 startingPage "11" @default.
• W2948441106 abstract "It has been well known for more than a decade, that iron overload adversely affects the prognosis of patients with lower-risk myelodysplastic syndromes (MDS) (Malcovati et al, 2005). Iron overload may be transfusion-related as well as being a consequence of increased intestinal iron uptake driven by hepcidin downregulation caused by dyserythropoiesis (Park et al, 2019) or genetic factors. In a recent study on neutrophils from 42 MDS patient samples with or without iron overload, the 14 patients with a ferritin level higher than 1000 µg/l, or more than 70% transferrin saturation, had a higher detectable 02.- and glutathione, detected by flow cytometry (Ivars et al, 2017). In turn, this excessive production of oxygen radicals contributes to organ damage, with hepatic and cardiac morbidity secondary to iron overload (de Montalembert et al, 2017), and may also impair haematopoiesis by increasing DNA instability. As a consequence, several recommendations have been made for iron chelation in MDS patients with a high transfusion burden or a high ferritin. These are largely based on the efficacy of chelation (Gattermann, 2008) and the survival benefit of chelation in beta-thalassaemia patients. Several groups have reported unexpected haematological responses resulting from iron chelation alone, with several haematological responses and even 3–20% of patients reaching transfusion independence with deferasirox (Gattermann et al, 2012; Angelucci et al, 2014). These observations suggest a beneficial effect of iron chelation on haematopoiesis. In addition, at the last American Society of Hematology meeting, the first results of a randomized prospective study of deferasirox compared to placebo in iron overloaded MDS patients (TELESTO) indicated that overall survival may be longer in patients receiving iron chelation (Angelucci et al, 2018). However, this study was underpowered because of its failure to reach the expected recruitment target, and most study events were related to cardiac morbidity. Therefore, the question of haematological (and outcome) improvement resulting from the reduction of oxidative stress by iron chelators remains an interesting hypothesis to explore. In the work published in this issue of the British Journal of Haematology, Jiménez-Solas et al (2019) explored this question in an elegant work on primary samples from MDS patients. The aim was to compare the ex vivo haematopoietic capacity of 14 primary bone marrow (BM) haematopoietic progenitors from patients with lower risk MDS, before and after 4–10 months of deferasirox treatment, with each patient used as their own control. In parallel, BM from 20 healthy donors was analysed. To assess haematopoiesis, colony-forming unit (CFU) assays were performed alongside detailed flow cytometric characterization with 2',7'–dichlorofluorescin diacetate (DCFDA) flow cytometry analyses, DNA oxidation and double-strand breaks, and Annexin-V apotosis assessment. The initial finding was that the intracellular reactive oxygen species (ROS) levels were higher in all MDS BM subpopulations, mostly in the CD34+, myeloid CD34+, granulocyte and monocyte populations. This was associated with DNA oxidation and early apoptosis mostly in the myeloid compartments. The growth of both granulocyte-macrophage and erythroid CFU (CFU-GM and CFU-E, respectively) was also impaired in MDS samples compared to controls. Following deferasirox treatment, global ROS levels were not reduced. However, there was a significant decrease in DNA oxidation and DNA double strand breaks in most BM subpopulations compared to pre-treatment levels. Furthermore, the authors observed that the CFU assays generated an increased number of myeloid colonies after deferasirox treatment, reaching the level of the control sample assays. In addition, the number of clusters, which was higher in the pre-treatment samples, decreased almost to the level of controls. By using a cluster/colony ratio, the authors indicated a strong post-treatment decrease of this marker, that is likely to represent a surrogate of haematopoiesis impairment. In our opinion, the impact of this work is important. Firstly, it strongly suggests the role of iron chelation on the clonogenic capacity and DNA damage in ex vivo haematopoietic progenitors. Even though the effect on intracellular ROS is not statistically significant, probably due to inter-patient heterogeneity of MDS pathophysiology, the functional changes observed may explain the unexpected haematopoietic responses observed in previously described cohorts of chelated MDS patients. It is noteworthy that a recent mutational screening study using next generation sequencing failed to correlate the mutational burden with haematological response to iron chelation in MDS patients with or without haematological improvement (Fabiani et al, 2019). Secondly, it opens the way for additional studies evaluating the antioxidant response, the magnitude of which could help us to understand why DNA damage secondary to oxidative stress (such as 8-Oxo-G) is modified by deferasirox treatment without impact on global ROS levels in some patients. This could also lead, in the future, to reduce the adverse impact of iron overload using strategies such as more aggressive iron chelation strategies or the combination of iron chelators with antioxidant agents. In this setting, the need for appropriate biomarkers to adapt treatment to each patient situation will be crucial. Emmanuel Gyan declares having received research funding, travel expenses and honoraria for consultancy work from Novartis. Antonio Almeida is on the speaker's bureau for Novartis and Celgene. Both authors interpreted the data, contributed to designing and writing the article and approved the final draft." @default.
• W2948441106 created "2019-06-14" @default.
• W2948441106 creator A5049023780 @default.
• W2948441106 creator A5052287429 @default.
• W2948441106 date "2019-06-06" @default.
• W2948441106 modified "2023-09-25" @default.
• W2948441106 title "Less iron improves MDS haematopoiesis" @default.
• W2948441106 cites W1964336930 @default.
• W2948441106 cites W2074001235 @default.
• W2948441106 cites W2086820492 @default.
• W2948441106 cites W2149982846 @default.
• W2948441106 cites W2594418167 @default.
• W2948441106 cites W2619238970 @default.
• W2948441106 cites W2894684082 @default.
• W2948441106 cites W2900440732 @default.
• W2948441106 cites W2904960901 @default.
• W2948441106 cites W2948098814 @default.
• W2948441106 doi "https://doi.org/10.1111/bjh.16012" @default.
• W2948441106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31172507" @default.
• W2948441106 hasPublicationYear "2019" @default.
• W2948441106 type Work @default.
• W2948441106 sameAs 2948441106 @default.
• W2948441106 citedByCount "1" @default.
• W2948441106 countsByYear W29484411062021 @default.
• W2948441106 crossrefType "journal-article" @default.
• W2948441106 hasAuthorship W2948441106A5049023780 @default.
• W2948441106 hasAuthorship W2948441106A5052287429 @default.
• W2948441106 hasBestOaLocation W29484411061 @default.
• W2948441106 hasConcept C109159458 @default.
• W2948441106 hasConcept C126322002 @default.
• W2948441106 hasConcept C153852466 @default.
• W2948441106 hasConcept C194409129 @default.
• W2948441106 hasConcept C203014093 @default.
• W2948441106 hasConcept C2776517179 @default.
• W2948441106 hasConcept C2776672577 @default.
• W2948441106 hasConcept C2776768029 @default.
• W2948441106 hasConcept C2777218474 @default.
• W2948441106 hasConcept C2777357209 @default.
• W2948441106 hasConcept C2777417653 @default.
• W2948441106 hasConcept C2777799968 @default.
• W2948441106 hasConcept C2778248108 @default.
• W2948441106 hasConcept C2778319317 @default.
• W2948441106 hasConcept C2780007613 @default.
• W2948441106 hasConcept C2780817109 @default.
• W2948441106 hasConcept C2781053155 @default.
• W2948441106 hasConcept C28328180 @default.
• W2948441106 hasConcept C54355233 @default.
• W2948441106 hasConcept C71924100 @default.
• W2948441106 hasConcept C86803240 @default.
• W2948441106 hasConcept C90924648 @default.
• W2948441106 hasConceptScore W2948441106C109159458 @default.
• W2948441106 hasConceptScore W2948441106C126322002 @default.
• W2948441106 hasConceptScore W2948441106C153852466 @default.
• W2948441106 hasConceptScore W2948441106C194409129 @default.
• W2948441106 hasConceptScore W2948441106C203014093 @default.
• W2948441106 hasConceptScore W2948441106C2776517179 @default.
• W2948441106 hasConceptScore W2948441106C2776672577 @default.
• W2948441106 hasConceptScore W2948441106C2776768029 @default.
• W2948441106 hasConceptScore W2948441106C2777218474 @default.
• W2948441106 hasConceptScore W2948441106C2777357209 @default.
• W2948441106 hasConceptScore W2948441106C2777417653 @default.
• W2948441106 hasConceptScore W2948441106C2777799968 @default.
• W2948441106 hasConceptScore W2948441106C2778248108 @default.
• W2948441106 hasConceptScore W2948441106C2778319317 @default.
• W2948441106 hasConceptScore W2948441106C2780007613 @default.
• W2948441106 hasConceptScore W2948441106C2780817109 @default.
• W2948441106 hasConceptScore W2948441106C2781053155 @default.
• W2948441106 hasConceptScore W2948441106C28328180 @default.
• W2948441106 hasConceptScore W2948441106C54355233 @default.
• W2948441106 hasConceptScore W2948441106C71924100 @default.
• W2948441106 hasConceptScore W2948441106C86803240 @default.
• W2948441106 hasConceptScore W2948441106C90924648 @default.
• W2948441106 hasIssue "1" @default.
• W2948441106 hasLocation W29484411061 @default.
• W2948441106 hasLocation W29484411062 @default.
• W2948441106 hasOpenAccess W2948441106 @default.
• W2948441106 hasPrimaryLocation W29484411061 @default.
• W2948441106 hasRelatedWork W2007465152 @default.
• W2948441106 hasRelatedWork W2035615233 @default.
• W2948441106 hasRelatedWork W2073806216 @default.
• W2948441106 hasRelatedWork W2397435675 @default.
• W2948441106 hasRelatedWork W2519136086 @default.
• W2948441106 hasRelatedWork W2777414596 @default.
• W2948441106 hasRelatedWork W2948441106 @default.
• W2948441106 hasRelatedWork W3036602249 @default.
• W2948441106 hasRelatedWork W4200475737 @default.
• W2948441106 hasRelatedWork W95673660 @default.
• W2948441106 hasVolume "187" @default.
• W2948441106 isParatext "false" @default.
• W2948441106 isRetracted "false" @default.
• W2948441106 magId "2948441106" @default.
• W2948441106 workType "article" @default.